Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageRepligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. As the overall market for biologics continues to grow and expand, our primary customers – global biopharmaceutical companies, contract development and manufacturing organizations and other life science companies (integrators) – face critical production cost, capacity, quality and time pressures.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Repligen Corporation (RGEN) reported revenue of $204M in Q2 2026 (quarter ended June 30, 2026), up 12% from the same quarter a year earlier. That came with a gross margin of 54% and net income of $5.0M (2.5% of revenue). For the full year FY2025, revenue was $738M (+16% year on year) and net income $49M.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
Ranks #11 of 27 by Smart Score